

**REMARKS**

Claims 1-4 and 9 are pending; claim 8 has been canceled. Support for the amendments are found as follows: Support for the amendments to claim 1 are found in original claims 5 and 7; support for the amendment to claim 3 is found throughout the specification, for example, at page 37, line 27. No new matter has been added.

Although Applicants do not acquiesce to the rejections made by the Examiner in the final Office Action, the claims have been amended to expedite prosecution and allowance of the claims. Applicants respectfully request reconsideration and allowance of the amended claims.

Applicants submit that no new fees are believed to be required, but hereby authorize the Commissioner to charge any additional claim fees to Deposit Account No. 16-0085, Reference No. 02312/2085B.

Applicants respectfully request entry of the above amendments.

Respectfully submitted,

Date: April 11, 2003

Barbara A. Gyde

Name: Barbara A. Gyde  
Registration No.: 34,614  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100

Marked Up Version:

1. A composition comprising a [an isolated] non-Goodpasture fragment of  $\alpha 3(\text{IV})$  NC1 domain and comprising amino acid residues 185-203 of SEQ ID NO:10, having at least one [or both] of the following activities [characteristics selected from the group consisting of]:
  - (a) an [the] ability to bind  $\alpha_v\beta_3$  integrin; and
  - (b) an [the] ability to inhibit proliferation of tumor [endothelial] cells; anda pharmaceutically-acceptable carrier.
2. The composition of Claim 1, wherein the ability to bind  $\alpha_v\beta_3$  integrin is RGD-independent.
3. The composition of Claim 2, wherein the tumor cells are melanoma cells [further comprising the inability to inhibit tumor cell proliferation].
4. An isolated fragment of  $\alpha 3(\text{IV})$  NC1 domain, having the amino acid sequence of amino acid residue 53 to amino acid 123 of SEQ ID NO:10.
8. Canceled.
9. An isolated fragment of  $\alpha 3(\text{IV})$  NC1 domain, having the amino acid sequence of amino acid residue 180 to amino acid residue 245 of SEQ ID NO:10.